Background: Routine laboratory reporting of estimated glomerular filtration rate (eGFR) may help clinicians detect kidney disease. The current national prevalence of eGFR reporting in clinical laboratories is unknown; thus, the extent of the situation of laboratories not routinely reporting eGFR with serum creatinine results is not quantified.
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E arly detection of chronic kidney disease (CKD) is critical to implementing preventive strategies; however, early detection can be challenging because of the absence of symptoms. Serum creatinine has historically been used as a key measure of kidney function; however, kidney function is poorly inferred from serum creatinine level alone because it is affected by multiple factors related to muscle mass, such as age, sex, race, and body size. Misinterpretation also may be a problem. A case study designed to test physician skills in interpreting serum creatinine results showed a tendency to overestimate kidney function and therefore underestimate kidney disease. 1 The National Kidney Disease Education Program (NKDEP), an initiative of the National Institutes of Health, recommends the use of estimated glomerular filtration rate (eGFR) instead of serum creatinine level alone to assess kidney function in adults older than 18 years. NKDEP and other organizations 2,3 encourage laboratories to estimate GFR by using the Modification of Diet in Renal Disease (MDRD) Study equation 4 and routinely report eGFR with all serum creatinine determinations. This practice has been associated with improved physician recognition of CKD in the primary care setting 5 and in elderly patients. 6 Laboratory reporting of eGFR appears to have increased during the past several years, possibly because of the inclusion of eGFR in clinical guidelines, an increase in the number of states with reporting mandates, and education efforts of various organizations. In 2003 and 2005, the College of American Pathologists (CAP), through its General Chemistry Survey, determined that 2.7% and 20.0% of respondents reported an eGFR result based on serum or plasma creatinine measurement, respectively. 7 However, the CAP studies included only laboratories that participate in the organization's proficiency testing program. Although these data provide a helpful snapshot of eGFR use and show that it has increased significantly among CAP proficiency testing participants, the CAP studies were not nationally representative of eGFR reporting and associated laboratory practices.
NKDEP designed a representative study to assess the prevalence of eGFR reporting in the United States and its territories and to characterize reporting and related practices. The objective is to determine the extent to which laboratory practices are consistent with recommendations made by NKDEP and other organizations. NKDEP recommends that laboratories 8 : (1) use the 4-variable MDRD Study equation 4 to calculate the result because it is useful for most patients and uses values that are easily accessible; (2) report eGFR with all serum creatinine determinations for adults 18 years and older when appropriate and feasible, primarily for the purpose of flagging CKD for clinicians who may not have been thinking about impaired kidney function; (3) report eGFR values of 60 mL/min/1.73 m 2 or greater simply as "Ն60 mL/min/1.73 m 2 ," not as an exact number, because interlaboratory variation among and imprecision of creatinine assays and the estimating equation result in greater inaccuracies for eGFR values at 60 mL/min/1.73 m 2 or greater 9 ; and (4) report serum creatinine to 2 decimal places (for milligrams per deciliter) to reduce rounding errors that may contribute to imprecision in eGFRs.
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Other study objectives are to generate data that provide a baseline useful for measuring the rate of adoption of eGFR reporting among US laboratories and gain insights into areas in which NKDEP and others might strategically focus efforts to increase or improve eGFR reporting. Our hypothesis is that laboratories conducting relatively greater volumes of serum creatinine tests are more likely than laboratories with lower volumes to report eGFR.
METHODS

Study Population and Sampling
On November 22, 2005, NKDEP obtained the Clinical Laboratory Improvement Amendments (CLIA) database from the Centers for Medicare & Medicaid Services, which includes all laboratories that hold or are seeking 1 of 4 types of certification required to perform laboratory tests on humans in the United States. The file includes laboratory/facility type (eg, community clinic and hospital), testing specialties and subspecialties, related annual test volumes, and other information. Of the nearly 200,000 laboratories in the CLIA database, we identified 20,532 that met the 2 inclusion criteria for this study: (1) possession of (or applying for) a Certificate of Compliance or Accreditation, and (2) a specialty in chemistry with a subspecialty in routine chemistry testing.
These 20,532 laboratories represent the universe of those that could be reporting eGFR and constitute the sample frame for this study. A sample was designed to allow results to be generalized to US-based clinical laboratories. The sample design maximized the precision of the estimated proportion of laboratories reporting eGFR for the national sample, as well as for 6 meaningful laboratory categories. The first 4 categories are those with the largest number of laboratories of 27 unique types of laboratories/facilities identified in the CLIA database. The 4 categories, accounting for 84.6% of all those that met the inclusion criteria, are physician office (7, 627) , hospital (6,574), independent (which traditionally conduct high test volumes; 2,174), and community clinic (986) laboratories. Samples were drawn from each of these 4 laboratory/facility types. The fifth category includes a small number of individual laboratories (28 in all) representing 3 laboratory types-public health (14), health fair (11) , and insurance (3)-that account for 60.5% of the total volume of routine chemistry tests performed nationally. The 28 were combined to form a single group of "highvolume" laboratories that would be examined separately. The sixth or "other" category represents the 3,143 laboratories from the remaining 20 laboratory/facility types. As a result, a total of 6 laboratory-type strata were created for sampling purposes. A minimum sample size was calculated for each of the 6 strata using a proportional sampling approach. Based on the 2005 CAP survey, the expected proportion of laboratories reporting eGFR was set to 0.20 and the desired level of precision was set to Ϯ2.0% with 95% confidence and corrected for each stratum's finite size. Taking into account the design effect of the stratified sample (design effect ϭ 1.24), the overall precision of the weighted national estimate was expected to provide a level of precision of Ϯ1%. Planning for an 80% response rate, according to Office of Management and Budget requirement, the sample size randomly drawn from each of the sampled strata was 1,599 physician office, 1,557 hospital, 1,125 independent, and 751 community clinic laboratories, all 28 high-volume laboratories (a census of all 3 laboratory types, not a sample), and 1,290 other. The total sample was 6,350 laboratories.
Instrument Development and Data Collection
NKDEP developed a 10-item questionnaire (Table 2) for both paper-and-pencil and web administration modes. The questions are based in part on survey questions used by CAP and 2 state departments of health that were known to have asked laboratories about eGFR-reporting practices. The paper-based instrument was pretested by laboratory professionals before implementation, and feedback was used to finetune the wording of questions and response selections. Although NKDEP was most interested in determining an estimate for the prevalence of eGFR reporting, the survey also provided an opportunity to ask questions related to the NKDEP reporting-related recommendations (see introduction). The web version was pretested by communication professionals to ensure that it was easy to use. On October 20, 2006, a cover letter and questionnaire, including a postage-paid return envelope, were mailed to the sample of 6,350 clinical laboratories. Addressed to laboratory directors/ managers, recipients were requested to either complete and return the paper questionnaire or log on to the NKDEP website to access the electronic questionnaire. One week later, a reminder postcard was mailed to the entire sample.
The initial mailing and postcard yielded a response rate of approximately 30.0%. A telephone reminder call was fielded to all nonresponders who had telephone numbers recorded in the sample database. During that telephone contact, if possible, survey data were directly collected by a trained interviewer to maximize response rates. This reminder/computerassisted telephone interview data collection effort was fielded between January 16 and February 13, 2007. A total of 4,013 laboratories responded across all 3 modes (52.7% telephone, 41.2% mail, and 6.1% web). The overall survey response rate was 63.4% (range, 58.2% to 78.6% across laboratory types). Data from all modes were merged and prepared for analysis. The number of laboratories excluded from analyses because of missing data is noted in the relevant data tables. 
Analysis
All analyses were conducted using SAS (version 9.1; SAS Institute, Cary, NC) PROC SURVEYFREQ. This procedure uses sampling weights and the finite population correction (FPC) to estimate the overall percentages, pooled variances, and 95% confidence intervals. The FPC was used in estimating the variance within strata, and the Rao-Scott 2 test 11 was used to test for differences among the strata. P values for comparisons among the first 4 strata were adjusted by using the stepdown Bonferroni method (SAS PROC MULTTEST). 12 Note that 22 of 28 possible responded in the public health/ insurance/health fair stratum. Although a small number, confidence intervals are still shown for this group and are expectedly wide for all items. Serum creatinine volume quartiles were developed for each stratum to test the hypothesis that higher volume laboratories are more likely than lower volume laboratories to report eGFR. This study was implemented after receiving clearance from the US Office of Management and Budget (Office of Management and Budget no. 0925-0570).
RESULTS
Serum Creatinine Reporting
Of laboratories performing routine chemistry tests for adult patients (survey item 1), 63.8% report a serum creatinine result (Table  3) . Serum creatinine reporting is highest in hospital (91.5%) and independent (70.7%) laboratories and lowest in physician office (45.9%) and other (48.4%) laboratories. Differences for the percentage of reporting across strata were significant at a level of P less than 0.001. When reporting serum creatinine in milligrams per deciliter (survey item 2), 90.5% report the value with 1 or no decimal places, whereas the remaining 9.5% report to 2 decimal places (data not shown).
eGFR Reporting
Of all laboratories that report serum creatinine, 38.4% calculate and report eGFR (survey item 5; Table 3 ). A statistical difference is seen across laboratory types (P Ͻ 0.001), with physician office laboratories, at 25.8%, the least likely to report eGFR compared with hospital, independent, or community clinic laboratories (P Ͻ 0.001). When the annual volume of serum creatinine tests (survey item 4) is examined by quartile, as listed in Table 4 , higher eGFR-reporting prevalence for laboratories at or greater than the median volume compared with less than the median was significant for the overall weighted estimates (P Ͻ 0.001) and most significant for physician office, hospital, and independent laboratories (all P Ͻ 0.001). In addition, eGFRreporting prevalence varies across categories, even in the laboratories with the highest test volumes (top 5%; P ϭ 0.01). Note: Values expressed as percentage (95% confidence interval). Abbreviation: eGFR, estimated glomerular filtration rate. *Does not include 9 laboratories that were not sure and 2 that refused to answer. P Ͻ 0.001 for comparison of the percentage reporting creatinine over stratum.
†A total of 2,528 laboratories reported serum creatinine. This table excludes 35 laboratories that did not know or did not answer the question about eGFR. P Ͻ 0.001 for comparison of the percentage reporting eGFR over stratum. P Ͻ 0.001 for pairwise comparisons of physician office laboratory to hospital, physician office laboratory to independent, and physician office laboratory to clinic; P ϭ 0.2 for hospital to independent, P ϭ 0.3 for hospital to clinic, and P ϭ 0.1 for independent to clinic. Pairwise comparisons are based on comparisons of the first 4 groups using the stepdown Bonferroni method. ‡Weighted percentage.
Protocol for Reporting eGFR
The majority (66.7%) of eGFR-reporting laboratories do so with all measured serum or plasma creatinine determinations (survey item 7). Alternatively, 25.0% report eGFR only when it is specifically requested, whereas 8.3% report for other reasons (eg, with certain panels or profiles, for patients of a certain age, or for outpatients; Table 5 ). A comparison across all laboratory types shows a significant difference in the percentage of laboratories that routinely report eGFR with all determinations (P Ͻ 0.001). Independent laboratories are least likely (50.6%) to report eGFRs with all determinations and most likely (45.5%) to report eGFRs when specifically requested. These estimates are significantly different from those for physician office (P ϭ 0.04), hospital (P Ͻ 0.001), and community clinic (P Ͻ 0.001) laboratories.
Estimating Equation and Reporting Convention
Almost 3 of 4 laboratories (71.6%) use the 4-variable MDRD Study equation (survey item 8), whereas another 14.3% use some other equation (eg, 6-variable MDRD Study equation or Cockcroft-Gault). Some responding laboratories (14.1%) did not know which equation was being used ( Table 5 ). Use of the MDRD Study equation ranged among laboratory types from 58.1% to 76.2% (P Ͻ 0.001). An eGFR reporting convention (survey item 9) of "Ͼ60 mL/min/1.73 m 2 " when the result is greater than 60 mL/min/ 1.73 m 2 is used by 45.3% of laboratories; however, 38.7% always report the exact numeric Note: Values listed as percent (95% confidence interval) unless noted otherwise. Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease. *Circumstances for reporting: 992 laboratories answered that they report eGFR. This table excludes 1 laboratory that skipped the question, 8 that answered "do not know," and 6 that supplied answers that did not make sense; P Ͻ 0.001 for comparison over stratum. Pairwise comparisons were calculated for reporting eGFR for all tests versus when requested or other for the first 4 strata. P ϭ 0.04 for independent comparison to physician office laboratory, P Ͻ 0.001 for independent comparison to community clinic and to hospital. P ϭ 0.5 for physician office laboratory comparison to hospital, P ϭ 0.08 for physician office laboratory comparison to clinic, and P ϭ 0.08 for hospital comparison to clinic. †Equation used: This table excludes 7 laboratories that skipped the question; P Ͻ 0.001 for comparison over stratum. ‡Reporting convention: This table excludes 10 laboratories that skipped the question; P ϭ 0.001 for comparison over stratum. Pairwise comparisons were calculated for greater than 60 versus exact for the first 4 strata. P ϭ 0.004 for clinic comparison to hospital, P ϭ 0.02 for clinic comparison to independent, P ϭ 0.09 for physician office laboratory comparison to hospital, P ϭ 0.2 for physician office laboratory comparison to independent, P ϭ 0.6 for physician office laboratory comparison to clinic, and P ϭ 0.9 for hospital comparison to independent. §Weighted percentage.
value. Another 5.5% use "Ͼ90 mL/min/1.73 m 2 " when reporting (Table 5) . Some (10.5%) respondents did not know the eGFR reporting convention being used. Differences in the reporting convention exist across laboratory types (P Ͻ 0.001). Community clinic laboratories are the least likely (28.3%) of all laboratory types to use "Ͼ60 mL/min/1.73 m 2 " when reporting.
Considering Reporting eGFR
Of laboratories not reporting eGFR, only 29.3% are currently considering reporting it, whereas 58.8% are not considering doing so. Another 11.9% of respondents reported that they are unsure of their laboratory's consideration of reporting (Table 6 ). This is significantly different across laboratory types (P Ͻ 0.001). Hospital laboratories (38.4%) are more likely to be considering eGFR reporting than other laboratory types, whereas community clinic (16.4%) and physician office laboratories (19.8%) are least likely to be considering reporting eGFR.
DISCUSSION
eGFR is currently the clinical standard for assessing kidney function; for detecting early CKD, monitoring kidney function, and assessing the effectiveness of treatment plans. NKDEP, along with others in the kidney community, has encouraged widespread adoption of eGFR reporting with all determinations for those 18 years and older to facilitate earlier diagnosis and treatment of CKD. This is especially important in the primary care setting, in which clinicians may routinely rely on serum creatinine alone to assess kidney function or may not be thinking about kidney disease when they order a metabolic panel for a particular patient. A national estimate for the prevalence of eGFR reporting was not available before this research was conducted. This baseline study yielded findings that fall into 3 areas, as discussed next.
1. The majority of laboratories are not reporting eGFR. Our findings indicate that more than half the serum creatinine-reporting laboratories are not reporting eGFR. We believe this is problematic because it likely represents a tremendous number of missed opportunities to diagnose CKD. This is especially true for clinicians using independent laboratories, which, as a group, conduct exceptionally high routine chemistry test volumes and have the third-highest number of facilities that do routine chemistry testing compared with the 26 other facility types in the CLIA database. 2. Improvements are necessary in laboratories already reporting eGFR. This study shows there is room for improvement in laboratories already reporting eGFR because many of their practices are not consistent with the recommendations outlined. For example, approximately 25.0% of eGFR-reporting laboratories do so only Abbreviations: eGFR, estimated glomerular filtration rate; CI, confidence interval. *P Ͻ 0.001 for comparison over stratum. Pairwise comparisons for yes versus no were calculated for the first 4 strata. P Ͻ 0.001 for comparison of physician office laboratory to hospital and hospital to clinic. P ϭ 0.04 for comparison of physician office laboratory to independent, physician office laboratory to clinic, hospital to independent, and independent to clinic laboratories.
†A total of 1,511 laboratories answered that they did not report eGFR; 47 laboratories that did not answer the question are excluded from this table.
‡Weighted percentage.
when specifically requested; that is, for clinicians already considering the possibility of kidney disease. Another concern is that only about half the independent laboratories report eGFR with all serum creatinine determinations. Again, given volumes of these laboratories, this may represent a significant number of missed opportunities to identify early CKD. The accuracy of eGFR also is a challenge because less than half the reporting laboratories (45.3%) and only 28.3% of laboratories in community clinics are using the "Ͼ60 mL/min/1.73 m 2 " reporting convention. Reporting exact numbers may be problematic if clinicians and patients attempt to track a decrease in kidney function by using eGFR results that are not valid. In addition, this study shows that virtually all eGFR results in the United States are calculated by using serum creatinine determinations reported to 1 or 0 decimal places (survey item 3; data not shown). The NKDEP Laboratory Working Group has called upon in vitro diagnostic companies to improve the precision of creatinine methods and develop instruments that report to 2 decimal places, both of which will improve the accuracy of eGFR determinations. 3. eGFR reporting is more common in laboratories serving higher risk patients and laboratories with relatively high test volumes. Stratum-and volume-level analyses of eGFR reporting yield 2 positive findings. Reporting is higher than the overall mean in hospital-and community clinicbased laboratories, which are facilities that commonly serve populations with high rates of CKD risk factors. In addition, for all laboratory categories, eGFR reporting prevalence is higher for laboratories with volumes greater than versus less than the median. Similarly, although the number of laboratories analyzed is relatively small, it appears that the eGFR-reporting prevalence is relatively high in the highestvolume laboratories overall (59.7%) and especially in laboratories in the independent (86.4%), other (75.0%), and hospital (64.1%) categories.
The study's limitations are those inherent to all research that relies upon "self-reporting," albeit across different modes. We expected respondents to be knowledgeable about their respective laboratory practices and use their records to retrieve information about serum creatinine testing volume in 2005. Instead, we observed that a small percentage of respondents were unsure about the equation and reporting convention used by the laboratory and found that many respondents left the volume item blank. The latter hindered our ability to determine precise prevalence estimates for eGFR reporting by volume, although we observed statistically significant differences in reporting prevalence for hospital and independent laboratories when we compared topversus bottom-half volumes. This limitation of course does not necessarily mean that survey results are inaccurate. Another possible limitation is that laboratories may have been more likely to respond to the survey if they reported serum creatinine than if they did not report serum creatinine.
Use of a previously existing database may present a second limitation because any errors in the CLIA database would have carried through to impact on the sampling design and study results. A third limitation, also associated with the database, was the absence of the names of laboratory directors and managers, our intended respondents. Our study correspondence was addressed to individuals with those or related titles, but it is unclear whether laboratory directors and managers were the individuals who completed the surveys/interviews. Completion of surveys by nonintended respondents may explain the cases in which the laboratory indicated it "did not know" or did not indicate the volume, as mentioned.
Additional research questions that future investigations may address include reasons laboratories are not reporting eGFR, reasons laboratories are not considering reporting eGFR, and the actual percentage of serum creatinine results that are reported with an eGFR by laboratories known to serve high-risk populations.
This baseline study has produced a relatively precise estimate for the prevalence of eGFR reporting and associated practices in US clinical laboratories during the end of 2006/beginning of 2007. Results can be used in future investigations to estimate the rate of adoption of eGFR
